Review article

Immunohistochemical expression of pd-l1 in solid tumors

Petra Radulović orcid.org/0000-0002-2902-0297 ; Department of Pathology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Božo Krušlin orcid.org/0000-0002-0480-1687 ; Department of Pathology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia

Abstract

Recent clinical trials have demonstrated that it is possible to induce durable remission in several tumors (non-small cell lung cancer (NSCLC), melanoma, squamous cancer of head and neck, renal cell carcinoma, Hodgkin lymphoma, colorectal cancer) by blocking the PD-1/PD-L1 (programmed death-1/programmed death-ligand 1) axis with anti-PD-1 or anti-PD-L1 antibodies and that an objective clinical response was closely associated with immunohistochemical PD-L1expression in tumor cells. Because immunohistochemistry is widely accepted and used method for PD-L1 assessment it is important to defi ne criteria for selecting patients who are candidates for immunotherapy and can benefi t from it.

Keywords

PD-1/PD-L1 pathway; immunotherapy; immunohistochemistry; solid tumors

Hrčak ID:

192122

URI

https://hrcak.srce.hr/192122

Publication date:

21.12.2017.

Article data in other languages: croatian

Visits: 2.375 *